Quick Answer
ARROWHEAD PHARMACEUTICALS, INC. reported Cash and Equivalents of $184.43 million for fiscal year 2021.
ARROWHEAD PHARMACEUTICALS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2021 | $184.43M | +28.5% |
| 2020 | $143.58M | -35.3% |
| 2019 | $221.80M | +636.1% |
| 2018 | $30.13M | +21.3% |
| 2017 | $24.84M | -70.9% |
| 2016 | $85.37M | +5.1% |
| 2015 | $81.21M | -38.7% |
| 2014 | $132.51M | +593.2% |
| 2013 | $19.11M | +466.0% |
| 2012 | $3.38M | -55.0% |
| 2011 | $7.51M | +9.6% |
| 2010 | $6.85M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| June 30, 2022 | $139.44M | -57.2% | +61.4% |
| March 31, 2022 | $86.41M | -76.8% | -5.7% |
| December 31, 2021 | $91.59M | -34.5% | -50.3% |
| September 30, 2021 | $184.43M | +28.5% | -43.4% |
| June 30, 2021 | $325.98M | +48.6% | -12.5% |
| March 31, 2021 | $372.38M | +45.1% | +166.1% |
| December 31, 2020 | $139.92M | -69.7% | -2.6% |
| September 30, 2020 | $143.58M | -35.3% | -34.5% |
- ARROWHEAD PHARMACEUTICALS, INC. showed an increase of +28.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2010–2021 period, ARROWHEAD PHARMACEUTICALS, INC.’s cash and equivalents has grown by 2593.6% (from $6.85 million to $184.43 million).
- The most recent figure is from ARROWHEAD PHARMACEUTICALS, INC.’s fiscal year 2021 report (Form 10-K), filed with the SEC on November 22, 2021.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: